Denali Therapeutics Inc. Stock News

SOUTH SAN FRANCISCO, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to

Denali Therapeutics Inc. (NASDAQ:DNLI) shares, rose in value on Friday, 03/11/22, with the stock price down by -2.50% to the previous day’s close as strong demand from buyers drove the stock to $30.39. Actively observing the price movement in the last trading, the stock closed the session at $31.17, falling within a range of $30.38 … Denali Therapeutics Inc. (NASDAQ: DNLI) Plunged -2.50%, So What Now? Read More »

Denali (DNLI) starts an early-stage study of DNL593 for treating frontotemporal dementia (FTD) due to mutations in the granulin gene (GRN) in collaboration with Takeda.

Denali (DNLI) starts an early-stage study of DNL593 for treating frontotemporal dementia (FTD) due to mutations in the granulin gene (GRN) in collaboration with Takeda.

Denali Therapeutics (DNLI) said it had begun dosing in a Phase 1/2 trial of its therapy, DNL593, to treat a type of dementia called frontotemporal dementia ((FTD)). FTD, which…

SOUTH SAN FRANCISCO, Calif., March 09, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today announced that dosing has begun in a Phase 1/2 clinical trial of DNL593 (PTV:PGRN) for the potential treatment of frontotemporal dementia (FTD) caused by mutations in the granulin gene ( GRN ). Pending initial clinical data from the Phase 1 healthy volunteer portion of the clinical trial, Denali expects to begin dosing individuals with FTD-GRN in the second half of 2022. Denali and Takeda have a strategic collaboration to co-develop and co-commercialize DNL593.

Denali Therapeutics Inc. (NASDAQ:DNLI)’s traded shares stood at 0.61 million during the last session, with the company’s beta value hitting 1.81. At the close of trading, the stock’s price was $30.45, to imply a decrease of -1.87% or -$0.58 in intraday trading. The DNLI share’s 52-week high remains $79.70, putting it -161.74% down since that … Denali Therapeutics Inc. (NASDAQ: DNLI) Has Succeeded In Gaining Momentum In 2022, The Stock Is Down -31.73% YTD Read More »

Denali (DNLI) announces wider-than-expected loss per share for fourth-quarter 2021. Revenues also miss estimates.

Denali (DNLI) announces wider-than-expected loss per share for fourth-quarter 2021. Revenues also miss estimates.

Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of -51.22% and 67.21%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the

Denali Therapeutics press release (NASDAQ:DNLI): Q4 GAAP EPS of -$0.62 misses by $0.16.Revenue of $12.51M (-96.1% Y/Y) misses by $32.31M.

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to c

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today reported financial results for the fourth quarter and year ended December 31, 2021, and provided business highlights.

Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of -51.22% and 67.21%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the